News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Teva to Acquire Emalex Biosciences to Strengthen Neuroscience Pipeline
Thursday, April 30, 2026Teva Pharmaceutical Industries has agreed to acquire Emalex Biosciences adding a latestage investigational therapy to its neuroscience pipeline as part of its growth strategy
FDA accepts NDA for zipalertinib to treat advanced NSCLC with EGFR exon 20 insertion mutations
Wednesday, April 29, 2026The US Food and Drug Administration has accepted a New Drug Application NDA for zipalertinib for the treatment of patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC with epidermal growth factor receptor EGFR exon insertion...
Terns Pharmaceuticals receives FDA Breakthrough Therapy Designation for TERN-701 in chronic myeloid leukaemia
Tuesday, April 28, 2026Terns Pharmaceuticals has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation to TERN for the treatment of adult patients with Philadelphia chromosomepositive chronic
Frost & Sullivan Identifies 10 Strategic Growth Opportunities Redefining Europe's Life Sciences Sector in 2026 with AI, Biotech, and Biomanufacturing Resilience
Friday, April 24, 2026Frost Sullivan highlights strategic growth opportunities in Europes life sciences sector for emphasizing AI integration biotech advancements and resilient biomanufacturing strategies
BIO-Europe Spring 2026 Partnering Momentum Builds as Global Biopharma Leaders Gear Up for Lisbon
Thursday, April 23, 2026Global biopharma leaders are ramping up partnering activities ahead of the th annual BIOEurope Spring in Lisbon highlighting Europes growing life sciences ecosystem
Dupixent approved in the U.S. for young children with uncontrolled chronic spontaneous urticaria
Thursday, April 23, 2026Regeneron Pharmaceuticals and Sanofi have received approval from the US Food and Drug Administration for Dupixent dupilumab to treat children aged to years with chronic spontaneous urticaria CSU
Europe Life Sciences 2026: 10 Strategic Growth Opportunities Redefining the Industry with AI, Biotech and Biomanufacturing Resilience
Wednesday, April 22, 2026Frost Sullivan identifies key strategic growth opportunities driving Europes life sciences sector in focusing on AI integration regulatory advancements and resilient biomanufacturing
Cristcot’s NDA for Next-Generation Hydrocortisone Suppository Accepted by FDA
Wednesday, April 22, 2026Cristcot a clinicalstage pharmaceutical company focused on gastrointestinal diseases has received acceptance from the US Food and Drug Administration FDA for its New Drug Application NDA for a nextgeneration
PHARMAP 2026 Kicks Off Today in Amsterdam Uniting Pharma Leaders on Manufacturing and Packaging Innovations
Tuesday, April 21, 2026PHARMAP Congress commenced today in the Netherlands gathering pharmaceutical industry leaders to explore Pharma sustainability security and cuttingedge manufacturing and packaging innovations
Biogen secures felzartamab rights in Greater China through TJ Biopharma agreement
Tuesday, April 21, 2026Biogen Inc has signed an agreement with TJ Biopharma to acquire exclusive rights to felzartamab in the Greater China region With this deal Biogen now holds worldwide rights to the drug candidate
